Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis
| Autor: | S. Todesco, U. Fiocco, M. Biscaro, P. Ostuni, A. Furlan, P. Sfriso, C. Botsios, L. Punzi |
|---|---|
| Jazyk: | English<br />Italian |
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Reumatismo, Vol 59, Iss 1, Pp 32-37 (2011) |
| Druh dokumentu: | article |
| ISSN: | 0048-7449 2240-2683 |
| DOI: | 10.4081/reumatismo.2007.32 |
| Popis: | Objective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.) or leflunomide (20 mg/die) in a two year observational study. Efficacy measures were assessed using the American College of Rheumatology (ACR) response criteria. Safety was evaluated according to a modified World Health Organization adverse reaction term dictionary. Results: At week 14, ACR 20% response criteria have been fulfilled by 53 (91.3%) out of 58 patients, 51 (87.9%) of them achieving also an ACR 50%and 15 (25.8%) an ACR 70%response. Thirteen patients touched 102 weeks of treatment: ACR 20% response was achieved in 92.3%, while ACR 50% and ACR 70% were respectively found in 84.6% and 38.4% of the cases. The mean decrease in HAQ score was 0.38, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|